Macrophage-Derived Vesicles for Endocytosis-Free Cargo Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering cargo, such as fluorescent markers, genetic material, and therapeutics, into cells face inefficiencies due to endocytic pathways trapping cargo in endosomal vesicles, and natural vesicles like exosomes have low production yields and complex separation procedures, limiting their therapeutic applications.
Innovation Solution
Macrophage-derived engineered vesicles (MEVs) are generated through nitrogen cavitation and centrifugation, allowing direct transport of cargo to target cells and modulating macrophage phenotype by shifting between pro-inflammatory (M1) and anti-inflammatory (M2) states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endocytic pathways are used for cargo delivery, then cargo can cross the cell membrane, but cargo is trapped in endosomal vesicles reducing delivery efficiency
Solution Approach 1:
The patent segments the delivery system into extracellular vesicles that can fuse with the plasma membrane, dividing the delivery process into membrane fusion and cargo release steps, thereby avoiding endosomal trapping
Solution Approach 2:
The patent uses cell-penetrating peptides as intermediaries that facilitate direct membrane translocation of cargo, serving as a mediator between the cargo and cell membrane to bypass endocytosis
2Ease of manufacture
If synthetic liposomes are used for cargo delivery, then loading is easy and in vitro delivery shows promise, but biocompatibility is limited due to immune system recognition
Solution Approach 1:
The patent changes the material composition parameter from synthetic phospholipids to natural membrane components, transforming the vesicles into immunologically compatible structures while retaining cargo delivery functionality
Solution Approach 2:
The patent creates composite vesicles by combining membrane proteins and lipids from donor cells with cargo, forming hybrid structures that possess both targeting specificity and immunocompatibility
3Reliability
If endogenous extracellular vesicles are used for targeted delivery, then immune evasion and cell type specificity are achieved, but production yield is low and separation procedures are complex
Solution Approach 1:
The patent performs preliminary action by inducing macrophage polarization to desired phenotypes before vesicle generation, ensuring the vesicles carry the appropriate surface markers for target cell recognition
Solution Approach 2:
The patent creates copies of functional vesicles by generating engineered vesicles from polarized macrophages that replicate the targeting and immunomodulatory properties of natural exosomes but with enhanced production efficiency
4Reliability
If macrophage polarization is modulated to treat disease, then therapeutic efficacy is enhanced, but complex cytokine signaling control is required
Solution Approach 1:
The patent extracts the complex cytokine signaling requirement by using pre-polarized macrophages as the source of vesicles, transferring the polarization state through vesicle surface markers rather than requiring active cytokine manipulation at the treatment site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MEVs effectively deliver cargo to target cells and repolarize macrophages, enhancing therapeutic efficacy by bypassing endocytosis and improving treatment outcomes for conditions like cancer and spinal cord injury.
Implementation Method 1
The cells are subjected to nitrogen cavitation at a pressure of 300 psi for 5 minutes.
Implementation Method 2
The cell lysate is then centrifuged at 4,000×g for 10 minutes, and the resulting pellet is discarded. The supernatant is then centrifuged at 10,000×g for 20 minutes.
Data Source
AI summary
Compositions and methods described in this document make use of macrophage-derived engineered vesicles (MEV) having specificity for delivery to a target environment, for use in modifying macrophage phenotype and/or treating a condition.